• Explore /
  • Poster
  • / AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab (pan) plus 5 fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer—A trial by the Australasian Gastro-Intestinal Trials Group (AGITG).

AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab (pan) plus 5 fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer—A trial by the Australasian Gastro-Intestinal Trials Group (AGITG).

Abstract Poster

Authors

null

Matthew E. Burge

Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia

Matthew E. Burge , David Espinoza , Katrin Marie Sjoquist , Derrick HW Siu , Rebecca Mercieca-Bebber , Lorraine A. Chantrill , Christos Stelios Karapetis , Christopher B. Steer , Sonia Yip , Jeff Cuff , Stephanie Winata , Jeanne Tie , Darshit Arunbhai Thaker , Niall C. Tebbutt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

ACTRN 12618000233224

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 3535)

DOI

10.1200/JCO.2024.42.16_suppl.3535

Abstract #

3535

Poster Bd #

198

Abstract Disclosures

Similar Posters

First Author: Kodai Takemori

First Author: Joan Maurel

First Author: Angela Damato

First Author: Jean-Louis Legoux